Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TLR4 | O00206 | 1/20 | 0.46 |
| ▸ | TLR2 | O60603 | 1/20 | 0.46 |
| ▸ | PARP10 | Q53GL7 | 9/20 | 0.46 |
| ▸ | PARP15 | Q460N3 | 8/20 | 0.46 |
| ▸ | PARP2 | Q9UGN5 | 1/20 | 0.43 |
| ▸ | HPGD | P15428 | 4/20 | 0.42 |
| ▸ | MAOA | P21397 | 1/20 | 0.40 |
| ▸ | MAOB | P27338 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16247136 | 0.91 | TLR4 (0.50) | TLR4TLR2PARP10PARP15PARP2 | |
| SCHEMBL4569118 | 0.84 | TLR4 (0.45) | TLR4TLR2PARP10PARP15PARP2 | |
| SCHEMBL27197634 | 0.84 | TLR4 (0.45) | TLR4TLR2PARP10PARP15PARP2 | |
| SCHEMBL18002090 | 0.80 | TLR4 (0.43) | TLR4TLR2PARP10PARP15PARP2 | |
| SCHEMBL20483478 | 0.80 | TLR4 (0.43) | TLR4TLR2PARP10PARP15HPGD | |
| SCHEMBL18002261 | 0.80 | TLR4 (0.43) | TLR4TLR2PARP10PARP15PARP2 | |
| SCHEMBL13881581 | 0.79 | TLR4 (0.44) | TLR4TLR2PARP10PARP15PARP2 | |
| SCHEMBL2207924 | 0.79 | TLR4 (0.66) | TLR4TLR2PARP10PARP15MAOA | |
| SCHEMBL31220908 | 0.79 | TLR4 (0.66) | TLR4TLR2PARP10PARP15MAOA | |
| SCHEMBL2208063 | 0.79 | TLR4 (0.66) | TLR4TLR2PARP10PARP15MAOA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230218549-A1 | ALKOXY COMPOUNDS FOR DISEASE TREATMENT | ACUCELA INC. | 2023-07-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230218549-A1 | ALKOXY COMPOUNDS FOR DISEASE TREATMENT | ALDH1A2, CLN6, AGER | TLR4 517/4885TLR2 890/4885PARP10 1846/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.